Clinical Trial

Therapeutic RSK1 Targeting in Myelofibrosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in participants with myelofibrosis (MF).The dose escalation portion utilizes a standard 3+3 design to evaluate two dose levels with an additional dose de-escalation portion to identify the recommended phase II dose (RP2D); subsequently, an additional 6 patients will be enrolled in the dose expansion portion evaluating the efficacy of PMD-026.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-23
notable Primary completion pushed: 2028-10-31 -> 2028-12-31 2026-04-22
minor Completion pushed: 2028-10-31 -> 2028-12-31 2026-04-22
Trial Details
NCT Number NCT07379125
Lead Sponsor Washington University School of Medicine
Collaborators: Phoenix Molecular Designs, The Foundation for Barnes-Jewish Hospital, Swim Across America
Conditions Myelofibrosis
Enrollment 18 participants
Start Date 2026-05-20
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22